Online Event, 1-2.30pm (AEST) Thursday 30 July
Featuring:
-
Rebecca Lang, Chair, AADC and CEO, QNADA
Why Harm Reduction is currently the most undervalued pillar of Australia’s National Drug Strategy -
Lucy Clynes, CEO, Hepatitis Australia
The new National Hepatitis Strategies – Priority Populations and Settings -
Ele Morrison, Deputy CEO, AIVL
How the harm reduction work of AIVL and its member organisations connects the priorities of the National Hepatitis and Drug Strategies -
John Ryan, CEO, Penington Institute
Overview of Penington’s Annual Overdose snapshot and policy implications -
Paul Dessauer, CEO, Peer Based Harm Reduction WA
Peer Based Harm Reduction WA: Case study of the scope of harm reduction work undertaken by peer-based drug user organisations - + Panel session and audience Q&A responding to the presentations and elaborating on the event topic